EGFR and non-small cell lung carcinoma: Early identification of advanced NSCLC patients with a poor response to the first- generation of EGFR-TKIs could facilitate tailored treatment and potentially enable the use of high-generation targeted therapy or combination therapy with chemotherapy or anti-angiogenesis, which has demonstrated a longer survival rate compared to the first-generation [17,37,38].